INVESTMENT STRATEGIES
Life Sciences
Life sciences investing examines the path from scientific evidence to a viable product. Capital needs to be assessed alongside development milestones, intellectual property and the requirements for commercialization.
Overview
Connecting scientific progress with development capital.
The discipline can include medicines, medical technologies and businesses supporting their development. Scientific promise and commercial value are related but distinct. A product may face further clinical work, regulatory review, manufacturing constraints or reimbursement challenges before it reaches a sustainable market position.
Investment focus
Therapeutic development
Capital associated with the research, clinical development or commercialization of medicines and related treatments.
Medical technology
Investments in devices, diagnostics and enabling technologies, evaluated through evidence, adoption and execution.
Development partnerships
Financing arrangements linked to specific programs, assets or milestones, with carefully defined economic rights.
Capital structure
Company equity, program-level development funding and negotiated royalty or milestone interests. The structure determines how funding obligations and economic participation are allocated.
Evaluation
Scientific evidence
Evaluate the strength of available data, study design and the uncertainties that further development must resolve.
Development pathway
Review regulatory steps, intellectual property, manufacturing readiness and the funding needed to reach milestones.
Commercial potential
Assess the clinical need, competing products, adoption barriers and the route to payment or reimbursement.
Risks to consider
Clinical studies can fail, regulatory outcomes are uncertain and intellectual property may be challenged. Development may require more time or capital than expected. A successful technical result may still fail to produce commercial demand. Losses can be substantial or total.
What evidence is required at the next milestone, and what happens if that milestone is not met?
These considerations are illustrative and not exhaustive. Evaluate any actual investment using its own documents, terms and risk disclosures.
Related strategies
This profile explains the investment discipline and potential structures. It does not constitute an offering of a particular fund or investment product.